Analyzing Auspex Pharmaceuticals (ASPX) and Its Peers

Auspex Pharmaceuticals (NASDAQ: ASPX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Auspex Pharmaceuticals to similar companies based on the strength of its dividends, earnings, risk, valuation, profitability, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Auspex Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Auspex Pharmaceuticals N/A N/A -36.85
Auspex Pharmaceuticals Competitors $290.27 million $35.99 million 57.28

Auspex Pharmaceuticals’ peers have higher revenue and earnings than Auspex Pharmaceuticals. Auspex Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Auspex Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auspex Pharmaceuticals 0 0 0 0 N/A
Auspex Pharmaceuticals Competitors 924 3343 11849 237 2.70

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.78%. Given Auspex Pharmaceuticals’ peers higher probable upside, analysts plainly believe Auspex Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Auspex Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auspex Pharmaceuticals N/A -61.66% -50.55%
Auspex Pharmaceuticals Competitors -5,189.81% -162.78% -35.24%

Summary

Auspex Pharmaceuticals peers beat Auspex Pharmaceuticals on 6 of the 8 factors compared.

Auspex Pharmaceuticals Company Profile

Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Receive News & Ratings for Auspex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.